Literature DB >> 9593137

Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.

B Ji1, S Sow, E Perani, C Lienhardt, V Diderot, J Grosset.   

Abstract

To develop a fully supervisable, monthly administered regimen for treatment of leprosy, the bactericidal effect of a single-dose combination of ofloxacin (OFLO) and minocycline (MINO), with or without rifampin (RMP), against Mycobacterium leprae was studied in the mouse footpad system and in previously untreated lepromatous leprosy patients. Bactericidal activity was measured by the proportional bactericidal method. In mouse experiments, the activity of a single dose of the combination OFLO-MINO was dosage related; the higher dosage of the combination displayed bactericidal activity which was significantly inferior to that of a single dose of RMP, whereas the lower dosage did not exhibit a bactericidal effect. In the clinical trial, 20 patients with previously untreated lepromatous leprosy were treated with a single dose consisting of either 600 mg of RMP plus 400 mg of OFLO and 100 mg of MINO or 400 mg of OFLO plus 100 mg of MINO. The OFLO-MINO combination exhibited definite bactericidal activity in 7 of 10 patients but was less bactericidal than the RMP-OFLO-MINO combination. Both combinations were well tolerated. Because of these promising results, a test of the efficacy of multiple doses of ROM in a larger clinical trial appears justified.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9593137      PMCID: PMC105755          DOI: 10.1128/AAC.42.5.1115

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  The bactericidal effect of rifampicin on M. leprae in man: a) single doses of 600, 900 and 1200 mg; and b) daily doses of 300 mg.

Authors:  L Levy; C C Shepard; P Fasal
Journal:  Int J Lepr Other Mycobact Dis       Date:  1976 Jan-Jun

2.  In vitro and in vivo activities of macrolides against Mycobacterium leprae.

Authors:  S G Franzblau; R C Hastings
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

3.  Activity of minocycline in Mycobacterium leprae-infected mice.

Authors:  R H Gelber
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

4.  The "proportional bactericidal test": a method for assessing bactericidal activity in drugs against Mycobacterium leprae in mice.

Authors:  M J Colston; G R Hilson; D K Banerjee
Journal:  Lepr Rev       Date:  1978-03       Impact factor: 0.537

5.  Clofazimine and dapsone compliance in leprosy.

Authors:  G A Ellard; V K Pannikar; K Jesudasan; M Christian
Journal:  Lepr Rev       Date:  1988-09       Impact factor: 0.537

6.  Rapid bactericidal effect of rifampin on Mycobacterium leprae.

Authors:  C C Shepard; L Levy; P Fasal
Journal:  Am J Trop Med Hyg       Date:  1972-07       Impact factor: 2.345

7.  Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae.

Authors:  C C Shepard; L Levy; P Fasal
Journal:  Am J Trop Med Hyg       Date:  1974-11       Impact factor: 2.345

8.  A method for counting acid-fast bacteria.

Authors:  C C Shepard; D H McRae
Journal:  Int J Lepr Other Mycobact Dis       Date:  1968 Jan-Mar

9.  Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae.

Authors:  C C Shepard
Journal:  Int J Lepr Other Mycobact Dis       Date:  1982-03

10.  Activity of ofloxacin against Mycobacterium leprae in the mouse.

Authors:  J H Grosset; C C Guelpa-Lauras; E G Perani; C Beoletto
Journal:  Int J Lepr Other Mycobact Dis       Date:  1988-06
View more
  12 in total

1.  Another view of the therapy of leprosy.

Authors:  R H Gelber
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

2.  Bactericidal activities of HMR 3647, moxifloxacin, and rifapentine against Mycobacterium leprae in mice.

Authors:  S Consigny; A Bentoucha; P Bonnafous; J Grosset; B Ji
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.

Authors:  Baohong Ji; Aurélie Chauffour; Koen Andries; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

4.  Performance of PCR-reverse blot hybridization assay for detection of rifampicin-resistant Mycobacterium leprae.

Authors:  Hye-young Wang; Hyunjung Kim; Yeun Kim; Hyeeun Bang; Jong-Pill Kim; Joo Hwan Hwang; Sang-Nae Cho; Tae Ue Kim; Hyeyoung Lee
Journal:  J Microbiol       Date:  2015-10-02       Impact factor: 3.422

5.  Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance.

Authors:  I Chopra; M Roberts
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

Review 6.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

7.  Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria.

Authors:  I Guillemin; V Jarlier; E Cambau
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

8.  Molecular assays for determining Mycobacterium leprae viability in tissues of experimentally infected mice.

Authors:  Grace L Davis; Nashone A Ray; Ramanuj Lahiri; Thomas P Gillis; James L Krahenbuhl; Diana L Williams; Linda B Adams
Journal:  PLoS Negl Trop Dis       Date:  2013-08-22

9.  Peripheral Neuropathy Due to Leprosy.

Authors:  Sharon P. Nations; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.972

10.  Leprosy therapy, past and present: can we hope to eliminate it?

Authors:  P V S Prasad; P K Kaviarasan
Journal:  Indian J Dermatol       Date:  2010-10       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.